Page 8 - Risk Evaluation News Today

(BPT) - The winter season can be a challenging time of year for many – one that can bring post-holiday financial stress and exhaustion. Amid darker, colder days, how do

(BPT) - The winter season can be a challenging time of year for many – one that can bring post-holiday financial stress and exhaustion. Amid darker, colder days, how do

Media reports touting ketamine as a miracle drug for severe depression have contributed to confusion about the differences between ketamine and its esketamine, experts said.

A federal judge has asked parties in a lawsuit challenging North Carolina’s abortion pill restrictions to submit new briefs by Feb. 5. After that date, the judge could issue a final decision without sending the case to trial.

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy. NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS protocol.

Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed as a distinctive therapy for Hypertrophic Cardiomyopathy.

Last year, the Governor signed into law a bill extending the application of the Public Employer Workplace Violence Prevention Act (the Act) to school districts and BOCES. The law went...

The FDA is evaluating reports of side effects such as hair loss and suicidal thoughts in people taking drugs like Ozempic, Mounjaro and Wegovy.

The US Food and Drug Administration is evaluating reports of side effects such as hair loss and suicidal thoughts in people taking medications like Ozempic, Mounjaro and Wegovy.